{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T01:32:44Z","timestamp":1768872764106,"version":"3.49.0"},"reference-count":35,"publisher":"Japan Atherosclerosis Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2023,9,1]]},"DOI":"10.5551\/jat.63849","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T22:12:43Z","timestamp":1669414363000},"page":"1198-1209","source":"Crossref","is-referenced-by-count":12,"title":["Hyperhomocysteinemia Increases Vascular Risk in Stroke Patients with Chronic Kidney Disease"],"prefix":"10.5551","volume":"30","author":[{"given":"Takafumi","family":"Mizuno","sequence":"first","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Ishizuka","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sono","family":"Toi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuntaro","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Wako","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Amarenco P, Lavall\u00e9e PC, Monteiro Tavares L, Labreuche J, Albers GW, Abboud H, Anticoli S, Audebert H, Bornstein NM, Caplan LR, Correia M, Donnan GA, Ferro JM, Gongora, Rivera F, Heide W, Hennerici MG, Kelly PJ, Kr\u00e1l M, Lin HF, Molina C, Park JM, Purroy F, Rothwell PM, Segura T, \u0160koloud\u00edk D, Steg PG, Touboul PJ, Uchiyama S, Vicaut \u00c9, Wang Y, Wong LKS, and TIAregistry.org Investigators. Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke. N Engl J Med, 2018; 378: 2182-2190","DOI":"10.1056\/NEJMoa1802712"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Hankey GJ. Potential new risk factors for ischemic stroke: what is their potential? Stroke, 2006; 37: 2181-2188","DOI":"10.1161\/01.STR.0000229883.72010.e4"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA, 2002; 288: 2015-2022","DOI":"10.1001\/jama.288.16.2015"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Wald DS, Law M and Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ, 2002; 325: 1202","DOI":"10.1136\/bmj.325.7374.1202"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Bostom AG and Culleton BF. Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol, 1999; 10: 891-900","DOI":"10.1681\/ASN.V104891"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, and Marsh EE: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke, 1993; 24: 35-41","DOI":"10.1161\/01.STR.24.1.35"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Refsum H, Ueland PM, Nyg\u00e5rd O, and Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med, 1998; 49: 31-62","DOI":"10.1146\/annurev.med.49.1.31"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet, 1998; 351: 1379-1387","DOI":"10.1016\/S0140-6736(97)09292-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Kronzon I and Tunick PA. Aortic atherosclerotic disease and stroke. Circulation, 2006; 114: 63-75","DOI":"10.1161\/CIRCULATIONAHA.105.593418"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Kim J, Kim H, Roh H, and Kwon Y. Causes of hyperhomocysteinemia and its pathological significance. Arch Pharm Res, 2018; 41: 372-383","DOI":"10.1007\/s12272-018-1016-4"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Selhub J, Jacques PF, Bostom AG, D\u2019Agostino RB, Wilson PW, Belanger AJ, O\u2019Leary DH, Wolf PA, Schaefer EJ, and Rosenberg IH. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med, 1995; 332: 286-291","DOI":"10.1056\/NEJM199502023320502"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Huang HW, Guo MH, Lin RJ, Chen YL, Luo Q, Zhang Y, and Wong KS. Hyperhomocysteinemia is a risk factor of middle cerebral artery stenosis. J Neurol, 2007; 254: 364-367","DOI":"10.1007\/s00415-006-0377-7"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Kim JM, Park KY, Shin DW, Park MS, and Kwon OS. Relation of serum homocysteine levels to cerebral artery calcification and atherosclerosis. Atherosclerosis, 2016; 254: 200-204","DOI":"10.1016\/j.atherosclerosis.2016.10.023"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Sen S, Oppenheimer SM, Lima J, and Cohen B. Risk factors for progression of aortic atheroma in stroke and transient ischemic attack patients. Stroke, 2002; 33: 930-935","DOI":"10.1161\/01.STR.0000014210.99337.D7"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Sen S, Reddy PL, Grewal RP, Busby, M, Chang P, and Hinderliter A. Hyperhomocysteinemia is Associated with Aortic Atheroma Progression in Stroke\/TIA Patients. Front Neurol, 2010; 1: 131","DOI":"10.3389\/fneur.2010.00131"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Dayal S, Arning E, Bottiglieri T, B\u00f6ger RH, Sigmund CD, Faraci FM, and Lentz SR. Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemic mice. Stroke, 2004; 35: 1957-1962","DOI":"10.1161\/01.STR.0000131749.81508.18"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Dayal S, Bottiglleri T, Arning E, Maeda N, Malinow MR, Sigmund CD, Heistad DD, Faraci FM, and Lentz SR. Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine beta-synthase-deficient mice. Cir Res, 2001; 88: 1203-1209","DOI":"10.1161\/hh1101.092180"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Bos MJ, van Goor ML, Koudstaal PJ, and Dippel DW. Plasma homocysteine is a risk factor for recurrent vascular events in young patients with an ischaemic stroke or TIA. J Neurol, 2005; 252: 332-337","DOI":"10.1007\/s00415-005-0647-9"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Kumral E, Saruhan G, Aktert D, and Orman M. Association of Hyperhomocysteinemia with Stroke Recurrence after Initial Stroke. J Stroke Cerebrovasc Dis, 2016; 25: 2047-2054","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.05.008"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Del Ser T, Barba R, Herranz AS, Seijas, V, L\u00f3pez-Manglano C, Domingo J, and Pondal M. Hyperhomocyst(e)inemia is a risk factor of secondary vascular events in stroke patients. Cerebrovasc Dis, 2001; 12: 91-98","DOI":"10.1159\/000047687"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Guttormsen AB, Ueland PM, Svarstad E, and Refsum H. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int, 1997; 52: 495-502","DOI":"10.1038\/ki.1997.359"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) van Guldener C, Kulik W, Berger R, Dijkstra DA, Jakobs C, Reijngoud DJ, Donker AJ, Stehouwer CD, and De Meer K. Homocysteine and methionine metabolism in ESRD: A stable isotope study. Kidney Int, 1999; 56: 1064-1071","DOI":"10.1046\/j.1523-1755.1999.00624.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Vinknes KJ, Refsum H, Turner C, Khaw KT, Wareham NJ, Forouhi NG, and Imamura F. Plasma Sulfur Amino Acids and Risk of Cerebrovascular Diseases: A Nested Case-Control Study in the EPIC-Norfolk Cohort. Stroke, 2021; 52: 172-180","DOI":"10.1161\/STROKEAHA.120.029177"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Dhar I, Lysne V, Seifert R, Svingen GFT, Ueland PM, and Nyg\u00e5rd OK. Plasma methionine and risk of acute myocardial infarction: Effect modification by established risk factors. Atherosclerosis, 2018; 272: 175-181","DOI":"10.1016\/j.atherosclerosis.2018.03.038"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Alfieri C, Ruzhytska O, Vettoretti S, Caldiroli L, Cozzolino M, and Messa P. Native Hypovitaminosis D in CKD Patients: From Experimental Evidence to Clinical Practice. Nutrients, 2019; 11: 1918","DOI":"10.3390\/nu11081918"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Longoni A, Kolling J, Siebert C, Dos Santos JP, da Silva JS, Pettenuzzo LF, Meira-Martins LA, Gon\u00e7alves CA, de Assis AM, and Wyse AT. 1,25-Dihydroxyvitamin D. Nutr Res, 2017; 38: 52-63","DOI":"10.1016\/j.nutres.2017.01.007"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol, 2010; 9: 855-865","DOI":"10.1016\/S1474-4422(10)70187-3"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA, 2004; 291: 565-575","DOI":"10.1001\/jama.291.5.565"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Hoshino T, Sissani L, Labreuche J, Bousser MG, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, Gabriel Steg P, Vicaut E, and Amarenco P. Non-cardioembolic stroke\/transient ischaemic attack in Asians and non-Asians: A post-hoc analysis of the PERFORM study. Eur Stroke J, 2019; 4: 65-74","DOI":"10.1177\/2396987318797245"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Hoshino T, Uchiyama S, Wong LKS, Kitagawa K, Charles H, Labreuche J, Lavall\u00e9e PC, Albers GW, Caplan LR, Donnan GA, Ferro JM, Hennerici MG, Molina C, Rothwell PM, Steg PG, Touboul PJ, Vicaut \u00c9, and Amarenco P: TIA registry.org Investigators. Five-Year Prognosis After TIA or Minor Ischemic Stroke in Asian and Non-Asian Populations. Neurology, 2021; 96: e54-e66","DOI":"10.1212\/WNL.0000000000010995"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Ducros V, Demuth K, Sauvant MP, Quillard M, Causs\u00e9 E, Candito M, Read MH, Drai J, Garcia I, Gerhardt MF, and SFBC Working group on homocysteine. French Society for Clinical Biology: Methods for homocysteine analysis and biological relevance of the results. J Chromatogr B Analyt Technol Biomed Life Sci, 2002; 781: 207-226","DOI":"10.1016\/S1570-0232(02)00497-X"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA, 1993; 270: 2693-2698","DOI":"10.1001\/jama.270.22.2693"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation, 1996; 93: 7-9","DOI":"10.1161\/01.CIR.93.1.7"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Nyg\u00e5rd O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland M, and Kv\u00e5le G. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA, 1995; 274: 1526-1533","DOI":"10.1001\/jama.274.19.1526"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Cravo ML, Gl\u00f3ria LM, Selhub J, et al. Hyperhomocysteinemia in chronic alcoholism: correlation with folate, vitamin B-12, and vitamin B-6 status. Am J Clin Nutr, 1996; 63: 220-224","DOI":"10.1093\/ajcn\/63.2.220"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/30\/9\/30_63849\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T04:49:41Z","timestamp":1693630181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/30\/9\/30_63849\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.63849","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]},"article-number":"63849"}}